Want to see MYO full AI Analyst Report?
MYO Stock Chart & Stats
$1.48
-$0.03(-3.00%)
At close: 4:00 PM EDT
$1.48
-$0.03(-3.00%)
Day’s Range― - ―
52-Week Range$0.61 - $1.89
Previous Close$0.97
Volume262.44K
Average Volume (3M)546.91K
Market Cap
$63.77M
Enterprise Value$51.03
Total Cash (Recent Filing)$13.45M
Total Debt (Recent Filing)$20.08M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Nov 11, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding39,607,853
10 Day Avg. Volume440,864
30 Day Avg. Volume546,914
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.34
Price to Sales (P/S)0.93
P/FCF Ratio-2.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.64Price Target Upside213.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$45.28M
Bulls Say, Bears Say
Bulls Say
Revenue Scale And GrowthRevenue has scaled meaningfully to $43.3M, with continued year-over-year growth indicating expanding adoption of the company’s products. Sustained top-line progress can support greater operating scale, broaden commercial reach, and create a foundation for future improvement in earnings power.
Strong Gross MarginA gross margin near 68% suggests Myomo retains substantial value after product costs, which provides room to fund commercial expansion and product support. If maintained as revenue grows, this margin profile could help the company convert scale into better operating leverage over time.
Differentiated MyoPro ProductMyoPro addresses functional movement needs for people with neuromuscular disorders and upper-limb weakness through wearable, signal-responsive assistance. This specialized medical-device offering can support defensible clinical positioning and continued demand as awareness and referrals expand.
Bears Say
Persistent Operating LossesLarge operating and net losses show that Myomo has not yet demonstrated durable operating leverage despite revenue growth and strong gross margins. Continued losses can constrain reinvestment, increase reliance on external funding, and delay the point at which growth produces self-sustaining earnings.
Negative And Worsening Cash FlowOngoing cash consumption means the business is not currently self-funding its operations, while the roughly 49% free-cash-flow deterioration signals added pressure. Persistent negative cash generation can reduce strategic flexibility and increase the need for financing during continued expansion.
Higher Leverage And Dilution RiskRising debt alongside shrinking equity has reduced balance-sheet flexibility and increases financing risk while losses persist. The approved increase in authorized shares adds funding capacity, but also creates potential dilution that could affect existing holders if capital is raised.
Myomo News
MYO FAQ
What was Myomo Inc’s price range in the past 12 months?
Myomo Inc lowest stock price was $0.60 and its highest was $1.89 in the past 12 months.
What is Myomo Inc’s market cap?
Myomo Inc’s market cap is $63.77M.
When is Myomo Inc’s upcoming earnings report date?
Myomo Inc’s upcoming earnings report date is Nov 11, 2026 which is in 44 days.
How were Myomo Inc’s earnings last quarter?
Myomo Inc released its earnings results on Aug 05, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.098 by $0.008.
Is Myomo Inc overvalued?
According to Wall Street analysts Myomo Inc’s price is currently Undervalued.
Does Myomo Inc pay dividends?
Myomo Inc does not currently pay dividends.
What is Myomo Inc’s EPS estimate?
Myomo Inc’s EPS estimate is -0.08.
How many shares outstanding does Myomo Inc have?
Myomo Inc has 39,607,853 shares outstanding.
What happened to Myomo Inc’s price movement after its last earnings report?
Myomo Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.098. Following the earnings report the stock price went up 23.585%.
Which hedge fund is a major shareholder of Myomo Inc?
Currently, no hedge funds are holding shares in MYO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Myomo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.64 (213.51% Upside)
$4.64 (213.51% Upside)
Blogger Sentiment
Bullish
MYO Sentiment 100%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Decreased
By 62.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $51.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
76.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Myomo Inc
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
MYO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights steady, incremental progress: modest top-line growth (Q1 revenue +3%), improved gross margin (+100 bps), lower operating expenses (-1%), improved adjusted EBITDA (negative $2.3M vs negative $2.8M), strong shifts toward recurring revenue (49% of revenue vs 25% prior year), and robust international and O&P channel growth (international +53% YoY; U.S. O&P +79% YoY). Management provided constructive operational updates including payer contracting (covered lives up to 158M), product advances (mobile app reducing material costs ~10%, MyoPro 3 development), and a growing referral network (150+ rehab facilities, Autoboc partnership). Lowlights include continued net losses, dependency on a multi-quarter revenue cycle, macro pressures in Medicare Advantage and a decline in Medicare Part B dollar contribution, and some short-term margin pressure from higher on-site fitting costs. Overall, positive operational momentum and improving financial metrics outweigh remaining profitability and execution risks.View all MYO earnings summariesMYO Stock 12 Month Forecast
Average Price Target
$4.64
▲(213.51% Upside)
Technical Analysis
Ownership Overview
9.32% Insiders
5.47% Mutual Funds
10.60% Other Institutional Investors
70.44% Public Companies and
Individual Investors